• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

128.59 +3.42 (+2.74%)
Streaming Delayed Price Updated: 1:38 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
September 11, 2025
Via ACCESS Newswire
News headline image
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025
August 26, 2025
Via ACCESS Newswire
News headline image
Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
August 25, 2025
Via ACCESS Newswire
News headline image
What 4 Analyst Ratings Have To Say About Protagonist Therapeutics ↗
August 07, 2025
 
Via Benzinga
News headline image
Protagonist (PTGX) Q2 Revenue Falls 26% ↗
August 07, 2025
Via The Motley Fool
News headline image
9 Analysts Assess Protagonist Therapeutics: What You Need To Know ↗
June 03, 2025
 
Via Benzinga
News headline image
Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 06, 2025
Via ACCESS Newswire
News headline image
Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis
July 21, 2025
Via ACCESS Newswire
News headline image
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? ↗
June 30, 2025
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide. 
Via Investor's Business Daily
News headline image
Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity
June 30, 2025
Via ACCESS Newswire
News headline image
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
June 26, 2025
Via ACCESS Newswire
News headline image
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
June 01, 2025
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025
May 21, 2025
Via ACCESS Newswire
News headline image
PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) showing some interesting technicals. Here's why. ↗
May 15, 2025
Interesting Technical Analysis finding for PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX): Indications Suggest NASDAQ:PTGX Could Be on the Verge of a Breakout. 
Via Chartmill
News headline image
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study ↗
May 09, 2025
Protagonist and J&J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at SID meeting. 
Via Benzinga
News headline image
Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting
May 09, 2025
Via ACCESS Newswire
News headline image
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 06, 2025
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025
April 23, 2025
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Reports Granting of Inducement Award
April 16, 2025
Via ACCESS Newswire
News headline image
Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study ↗
April 10, 2025
Protagonist and Johnson & Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high clearance rates and favorable safety. 
Via Benzinga
News headline image
Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill
April 10, 2025
Via ACCESS Newswire
News headline image
Does PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) align with Mark Minervini’s trading strategy? ↗
April 05, 2025
Should you consider PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) for high growth investing? A fundamental and technical analysis of (NASDAQ:PTGX). 
Via Chartmill
News headline image
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
March 18, 2025
Via ACCESS Newswire
News headline image
D-Wave Quantum And IonQ Are Among Top Mid-Cap Stock Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio? ↗
March 16, 2025
Mid-cap stocks were top performers last week. D-Wave, Protagonist, Veren, IonQ, Rigetti, Semtech, Orla Mining, and Hesai all saw significant gains. 
Via Benzinga
News headline image
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
March 11, 2025
 
Via Benzinga
News headline image
Keep an eye on the top gainers and losers in Monday's session. ↗
March 10, 2025
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
Monday's session: top gainers and losers ↗
March 10, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
March 10, 2025
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Redfin, Mineralys Therapeutics, Trevi Therapeutics And Other Big Stocks Moving Higher On Monday ↗
March 10, 2025
 
Via Benzinga
News headline image
Top movers in Monday's pre-market session ↗
March 10, 2025
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap